Bio-Techne
Public | |
Traded as | |
Industry |
|
Founded | 1976 |
Founder | Dr. Roger C. Lucas |
Headquarters | Minneapolis, Minnesota, United States |
Area served | Worldwide |
Key people | Chuck Kummeth (President, CEO) |
Products | Proteins, antibodies, immunoassays, small molecules, cell culture media, in situ hybridization products, protein analysis instruments, diagnostic controls, calibrators, blood gas and clinical chemistry controls |
Revenue |
|
Number of employees | >2,100 (2018) |
Website | Bio-Techne |
Footnotes / references [1][2] |
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.[2] The company's brands include flagship R&D Systems (Research and Diagnostic Systems Inc.),[3] Novus Biologicals, Tocris Bioscience, ProteinSimple, Exosome Diagnostics, BiosPacific, Cliniqa, Advanced Cell Diagnostics, RNA Medical, Bionostics and BostonBiochem.[2][4] The company's products are used in both clinical and research contexts.[5][6] The company was co-founded as a "hematology controls developer"[2] by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.[7]
Bio-Techne is listed on the NASDAQ under the ticker symbol TECH.[8] Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...",[9] a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch.[10] Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."[11]
Beginning in 2013, the company's chief executive officer was Charles (Chuck) Kummeth, who had previously been employed by 3M and Thermo Fisher Scientific.[2]
In an article by the Star Tribune, Joe Carlson wrote "Analysts like how Bio-Techne is growing, combining well-considered acquisition targets with the company's long-running reputation for producing top-quality raw proteins and antibodies for use in research."[12]
Acquisitions
- 2013: Bionostics for $104 million[13]
- 2014: Novus Biologicals for $60 million,[14] ProteinSimple for $300 million,[15] PrimeGene,[2] CyVek[2]
- 2015: Cliniqa Corporation[16]
- 2016: Zephyrus Biosciences[17] Advanced Cell Diagnostics for $325 million[18]
- 2017: Trevigen[19]
- 2018: Atlanta Biologicals[20], Quad Technologies[21], Exosome Diagnostics for up to $575 million [22]
References
- ↑ "Form 10-K". EDGAR. U.S. Securities and Exchange Commission. August 31, 2015. p. 34. Retrieved 2016-07-25.
- 1 2 3 4 5 6 7 Dutton, Gail (June 15, 2014). "Bio-Techne Realigns for Growth". GEN Corporate Profile. Genetic Engineering & Biotechnology News. 34 (12): 10. Retrieved 2016-07-24.
- ↑ Murphy, Barbara (May 12, 1998). "Amgen Inc. Sells Its Stake in Techne Corp". Los Angeles Times. Retrieved 2015-04-25.
Techne is the parent company for Research and Diagnostic Systems Inc.
- ↑ "Bio-Techne Corporation Brands: Bio-Techne". www.bio-techne.com. Retrieved 2018-08-05.
- ↑ Meguru Miyamoto; Kazuyuki Ishihara & Katsuji Okuda (April 2006). "The Treponema denticola Surface Protease Dentilisin Degrades Interleukin-1β (IL-1β), IL-6, and Tumor Necrosis Factor Alpha". Infection and Immunity. 74 (4): 2462&ndash, 2467. doi:10.1128/IAI.74.4.2462-2467.2006. PMC 1418930. PMID 16552080.
- ↑ C-C Chang; et al. (November 23, 2012). "CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation". Cell Death & Differentiation. 20: 443&ndash, 455. doi:10.1038/cdd.2012.136. PMC 3569983. Retrieved 2015-04-25.
- ↑ "Roger C. Lucas Ph.D." Executive Profile & Biography. Businessweek. Retrieved 2015-04-25.
Dr. Roger C. Lucas, Ph.D. co-founded Techne Corp., in 1985 and serves as its Chief Scientific Advisor.
- ↑ "Bio-Techne Corp". Yahoo! Finance. Retrieved 2015-04-25.
- ↑ Reese, John P. (October 13, 2010). "China Picks Buffett Might Like". Forbes. TECHNE Corporation (TECH). Retrieved 2015-04-25.
TECHNE’s management also appears to be doing a solid job
- ↑ Doorn, Philip van (March 2, 2015). "These are the most profitable Nasdaq biotech companies". Dow Jones MarketWatch. Retrieved 2015-04-25.
- ↑ Carole Gould (September 3, 2000). "Investing With: Edward B. White". The New York Times. Retrieved 2015-04-25.
praising the chief executive, Thomas Oland, as a "deeply committed scientist."
- ↑ "Biotech firm carves a large niche in tools for research". Retrieved 2018-08-05.
- ↑ "Techne to buy Bionostics for $104m in cash". boston.com. Associated Press. June 18, 2013. Retrieved 2015-04-25.
buy Bionostics Holdings Ltd. and its operating subsidiary Bionostics Inc. for $104 million in cash.
- ↑ "Bio-Techne Announces Agreement To Acquire Novus Biologicals" (Press release). Bio-Techne. July 2, 2014. Retrieved 2015-04-25 – via PR Newswire.
- ↑ "Bio-Techne Announces ProteinSimple Acquisition Completion" (Press release). Bio-Techne. August 1, 2014. Retrieved 2015-04-27.
- ↑ "Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation" (Press release). Bio-Techne. June 5, 2015. Retrieved 2016-05-29 – via PR Newswire.
- ↑ Staff (March 21, 2016). "Bio-Techne Acquires Zephyrus Biosciences". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2016-07-24.
- ↑ Staff (July 21, 2016). "Bio-Techne to Acquire Advanced Cell Diagnostics for Up to $325M". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2016-07-24.
- ↑ "Bio-Techne Acquires Trevigen Inc". PR Newswire. Retrieved 2018-04-10.
- ↑ "Bio-Techne Acquires Atlanta Biologicals Inc". PR Newswire. Retrieved 2018-04-10.
- ↑
- ↑ "Bio-Techne closes $250M Exosome Diagnostics takeover". MedTech Dive. Retrieved 2018-08-05.
External links
- Business data for Bio-Techne Corporation:
- Reuters
- SEC filings
- ↑ "Bio-Techne To Acquires Quad Technologies". PR Newswire. Retrieved 2018-07-27.